Table 1. Summary of approved CAR T-cell... | American Society of Hematology

Table 1.

Summary of approved CAR T-cell and BsAb products in LBCL, FL, and MCL

Disease	Product	Line	Response∗				Toxicity, grade 3+
Disease	Product	Line	ORR, %	CRR, %	PFS, mo	DOR, mo	CRS, %	NT, %	Cytopenias, %†	Infections, %
LBCL	Axi-cel	3+⁴^,⁵	83	58	5.9	11.1	13	28	78	NI
		2⁶^,⁷	83	65	14.7	41.7	6	21	69	14
	Liso-cel	3+⁸^,⁹	73	53	6.8	23.1	2	10	60	12
		2¹⁰^,¹¹	87	74	NR	NR	1	4	80	15
		NTE¹²^,¹³	80	54	9.0	23.3	2	5	48	7
	Tisa-cel	3+¹⁴^,¹⁵	53	39	2.9	NR	22	12	39	20
	Epcoritamab	3+¹⁶	63	39	4.4	12.0	3	1	15	15
	Glofitamab	3+¹⁷	52	39	4.9	18.4	4	3	27	15
FL	Axi-cel	3+¹⁸^,¹⁹^,²⁰	94	79	57.3	55.5	6	15	33	18
	Tisa-cel	3+²¹^,²²	86	68	NR	NR	0	1	32	5
	Liso-cel	3+²³^,²⁴	97	94	NR	NR	1	2	58	5
	Mosunetuzumab	3+^25-27	78	60	24.0	35.9	2	0	26	14
	Epcoritamab	3+²⁸^,²⁹	82	63	15.4	NR	2	0	30	40
MCL	Brexu-cel	2+³⁰^,³¹	91	68	25.8	28.2	15	31	85	32
	Liso-cel	3+³²	83	72	15.3	15.7	1	9	56	15

Disease	Product	Line	Response∗				Toxicity, grade 3+
Disease	Product	Line	ORR, %	CRR, %	PFS, mo	DOR, mo	CRS, %	NT, %	Cytopenias, %†	Infections, %
LBCL	Axi-cel	3+⁴^,⁵	83	58	5.9	11.1	13	28	78	NI
		2⁶^,⁷	83	65	14.7	41.7	6	21	69	14
	Liso-cel	3+⁸^,⁹	73	53	6.8	23.1	2	10	60	12
		2¹⁰^,¹¹	87	74	NR	NR	1	4	80	15
		NTE¹²^,¹³	80	54	9.0	23.3	2	5	48	7
	Tisa-cel	3+¹⁴^,¹⁵	53	39	2.9	NR	22	12	39	20
	Epcoritamab	3+¹⁶	63	39	4.4	12.0	3	1	15	15
	Glofitamab	3+¹⁷	52	39	4.9	18.4	4	3	27	15
FL	Axi-cel	3+¹⁸^,¹⁹^,²⁰	94	79	57.3	55.5	6	15	33	18
	Tisa-cel	3+²¹^,²²	86	68	NR	NR	0	1	32	5
	Liso-cel	3+²³^,²⁴	97	94	NR	NR	1	2	58	5
	Mosunetuzumab	3+^25-27	78	60	24.0	35.9	2	0	26	14
	Epcoritamab	3+²⁸^,²⁹	82	63	15.4	NR	2	0	30	40
MCL	Brexu-cel	2+³⁰^,³¹	91	68	25.8	28.2	15	31	85	32
	Liso-cel	3+³²	83	72	15.3	15.7	1	9	56	15

NTE, non–transplant eligible; NI, not included; NT, neurologic toxicity.

Response data included from publication with longest follow-up when applicable.

Highest incidence of most common grade ≥3 cytopenia from listed rates of anemia, thrombocytopenia, and neutropenia.